Loading...
Market
What will be the regulatory approval status of vortioxetine for glioblastoma treatment by December 31, 2025?
2
Resolution / Starting Odds
Approved by FDA • 25%
Approved by EMA • 25%
Approved by both FDA and EMA • 25%
Not approved • 25%
FDA announcements, EMA announcements, other regulatory bodies' announcements
Story
£40 Antidepressant Vortioxetine Found Effective Against Glioblastomas in ETH Zurich Study
Sep 20, 2024, 10:29 AM
Researchers have discovered that vortioxetine, a widely available antidepressant costing £40, shows unexpected effectiveness in treating glioblastomas, the most common and aggressive type of brain tumour. Studies conducted in cell cultures and mice by ETH Zurich and other research teams demonstrated that the drug can shrink tumours and kill tumour cells. This breakthrough suggests that vortioxetine could be repurposed to combat glioblastomas, offering a potentially new treatment avenue for this deadly brain cancer.
View original story
Similar markets
Approved • 25%
Not Approved • 25%
Approval Pending • 25%
Withdrawn • 25%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Only in the US • 25%
Only in the EU • 25%
In both US and EU • 25%
In US, EU, and Japan • 25%
Approved in the US only • 25%
Approved in the EU only • 25%
Approved in both US and EU • 25%
Not approved in either region • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
